KRAS and neoplasm: Such an analysis – extended to additional molecular markers similar to IGF1R/EGFR expression levels and receptor mutations, as well as alterations of key signalling molecules, such as PTEN, p53 or k-ras – may help to achieve individual tumour characterisation to increase response rates to treatment, reduce side effects and avoid therapy resistance.